survival analysis

Transformative Survival Gains in Cystic Fibrosis: A Population-Level Evaluation of CFTR Modulator Therapy Effectiveness

By MedXY 05/14/2026

A large-scale retrospective study using US CFF Registry data reveals that CFTR modulator therapy reduces the hazard of death by 66% over an eight-year period, marking a significant milestone in cystic fibrosis clinical outcomes and life expectancy.

AI Neurology news

AI-Driven Prognosis: EEGSurvNet Accurately Predicts Seizure Timing From Routine EEG Data

By MedXY 01/28/2026

Researchers developed EEGSurvNet, a deep survival model that analyzes routine EEG to predict seizure risk over two years. Outperforming clinical models, it achieved an AUROC of 0.80 at two months and showed high efficacy in patients without visible epileptiform discharges.

news Oncology Urology

Integrating Local and Metastasis-Directed Therapies Redefines Survival in Oligometastatic Prostate Cancer: Evidence from an Umbrella Review

By MedXY 01/08/2026

An umbrella review of 21 meta-analyses involving 160,000 patients confirms that prostate radiotherapy and metastasis-directed therapy significantly improve survival and progression control in oligometastatic prostate cancer, establishing a new multimodal standard of care.

news Oncology

Navigating Non-Proportional Hazards in Hepatocellular Carcinoma Trials: Enhancing Interim Analysis Accuracy

By MedXY 10/28/2025

Non-proportional hazards in hepatocellular carcinoma immunotherapy trials can distort interim and final survival outcomes. Employing tailored statistical strategies ensures robust, clinically meaningful analyses and informed decision-making.

Clinical Updates news Oncology Specialties

Decoding Oncology Trial Endpoints: OS, DFS, PFS, ORR, CR, PR, SD, PD, and DCR Explained

By MedXY 08/06/2025

This article demystifies key clinical trial efficacy endpoints in oncology, including OS, DFS, PFS, ORR, CR, PR, SD, PD, and DCR, providing clinicians with a practical guide to their definitions, roles, and interpretation.